These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Grant-Klein RJ; Altamura LA; Badger CV; Bounds CE; Van Deusen NM; Kwilas SA; Vu HA; Warfield KL; Hooper JW; Hannaman D; Dupuy LC; Schmaljohn CS Hum Vaccin Immunother; 2015; 11(8):1991-2004. PubMed ID: 25996997 [TBL] [Abstract][Full Text] [Related]
48. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Cap AP; Pidcoke HF; Keil SD; Staples HM; Anantpadma M; Carrion R; Davey RA; Frazer-Abel A; Taylor AL; Gonzales R; Patterson JL; Goodrich RP Transfusion; 2016 Mar; 56 Suppl 1(Suppl 1):S6-15. PubMed ID: 27001363 [TBL] [Abstract][Full Text] [Related]
49. Modeling Ebola Virus Transmission Using Ferrets. de La Vega MA; Soule G; Tran KN; Tierney K; He S; Wong G; Qiu X; Kobinger GP mSphere; 2018 Oct; 3(5):. PubMed ID: 30381349 [TBL] [Abstract][Full Text] [Related]
50. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys. Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S J Virol; 2017 May; 91(10):. PubMed ID: 28250127 [TBL] [Abstract][Full Text] [Related]
51. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Reed DS; Lackemeyer MG; Garza NL; Sullivan LJ; Nichols DK Microbes Infect; 2011 Oct; 13(11):930-6. PubMed ID: 21651988 [TBL] [Abstract][Full Text] [Related]
53. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. Jones SM; Stroher U; Fernando L; Qiu X; Alimonti J; Melito P; Bray M; Klenk HD; Feldmann H J Infect Dis; 2007 Nov; 196 Suppl 2():S404-12. PubMed ID: 17940977 [TBL] [Abstract][Full Text] [Related]
55. Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Thi EP; Lee AC; Geisbert JB; Ursic-Bedoya R; Agans KN; Robbins M; Deer DJ; Fenton KA; Kondratowicz AS; MacLachlan I; Geisbert TW; Mire CE Nat Microbiol; 2016 Aug; 1(10):16142. PubMed ID: 27670117 [TBL] [Abstract][Full Text] [Related]
56. Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. Volchkova VA; Dolnik O; Martinez MJ; Reynard O; Volchkov VE J Infect Dis; 2011 Nov; 204 Suppl 3():S941-6. PubMed ID: 21987773 [TBL] [Abstract][Full Text] [Related]
57. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection. Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457 [TBL] [Abstract][Full Text] [Related]
58. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston). Morikawa S; Saijo M; Kurane I Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):391-8. PubMed ID: 17610952 [TBL] [Abstract][Full Text] [Related]
59. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432 [TBL] [Abstract][Full Text] [Related]
60. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Dowall SD; Jacquot F; Landon J; Rayner E; Hall G; Carbonnelle C; Raoul H; Pannetier D; Cameron I; Coxon R; Al Abdulla I; Hewson R; Carroll MW Sci Rep; 2017 Jun; 7(1):4099. PubMed ID: 28642489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]